We are developing NRL-3, a proprietary nasal spray formulation of a benzodiazepine (other than diazepam) and Intravail®, for the acute treatment of status epilepticus (SE).* There are an estimated 152,000 SE cases per year in the United States, resulting in 42,000 deaths and an inpatient medical treatment cost of up to $7.0 billion per year. We believe NRL-3, if approved, has the potential to enable caregivers to treat patients experiencing SE and potentially cease their seizure activity. We expect to submit our IND and begin clinical trials in 2022.
*NRL-3 is an investigational product candidate that has not been approved by FDA for any indication.